Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13178103 | 0.88 | HPGD (0.36) | HPGDCNR1CNR2POLBTDP1 | |
| SCHEMBL4971014 | 0.84 | POLB (0.39) | HPGDCNR1CNR2POLBTDP1 | |
| SCHEMBL18484551 | 0.77 | NAMPT (0.34) | HPGDCNR1CNR2POLBKDM4E | |
| SCHEMBL4528244 | 0.75 | NPSR1 (0.48) | HPGDCNR1CNR2TDP1MEN1 | |
| SCHEMBL14820408 | 0.74 | NAMPT (0.36) | HPGDPOLBTDP1KDM4ENAMPT | |
| SCHEMBL18232491 | 0.74 | TDP1 (0.46) | CNR1CNR2TDP1KMT2A | |
| SCHEMBL10270128 | 0.72 | EPHX1 (0.55) | HPGDPOLBTDP1MEN1KMT2A | |
| SCHEMBL21950057 | 0.72 | KMT2A (0.35) | HPGDPOLBTDP1KDM4EPTGIR | |
| SCHEMBL23135475 | 0.72 | CNR2 (0.47) | HPGDCNR1CNR2TDP1MEN1 | |
| SCHEMBL26014495 | 0.72 | TDP1 (0.45) | HPGDTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | HPGD 415/4885CNR1 1969/4885CNR2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.